Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S.L. Friedman.
Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury.
J Biol Chem, 275 (2000), pp. 2247-2250
[2.]
G. Ballardini, S. Degli Esposti, F.B. Bianchi, L.B. De Giorgi, A. Faccani, L. Biolchini, et al.
Correlation between Ito cells and fibrogenesis in an experimental model of hepatic fibrosis. A sequential stereological study.
Liver, 3 (1983), pp. 48-63
[3.]
F.J. Eng, S.L. Friedman, I. Fibrogenesis.
New insight into hepatic stellate cell activation: the simple becomes complex.
Am J Physiol, 279 (2000), pp. G7-G11
[4.]
J.J. Maher.
Leukocytes as modulators of stellate cell activation.
Alcohol Clin Exp Res, 23 (1999), pp. 917-921
[5.]
M. Pinzani, F. Marra.
Cytokine receptors and signaling in hepatic stellate cells.
Semin Liver Dis, 21 (2001), pp. 397-416
[6.]
D. Schuppan, M. Ruehl, R. Somasundaram, E.G. Hahn.
Matrix as a modulator of hepatic fibrogenesis.
Semin Liver Dis, 21 (2002), pp. 351-372
[7.]
F.J. Eng, S.L. Friedman.
Transcriptional regulation in hepatic stellate cells.
Semin Liver Dis, 21 (2001), pp. 385-395
[8.]
D.C. Rockey.
Hepatic blood flow regulation by stellate cells in normal and injured liver.
Semin Liver Dis, 21 (2001), pp. 337-349
[9.]
M. Pinzani, A. Gentilini, A. Caligiuri, R. De Franco, G. Pellegrini, S. Milani, et al.
Transforming growth factor b1 regulates platelet-derived growth factor subunit in human lier fat-storing cells.
Hepatology, 21 (1995), pp. 232-239
[10.]
M. Pinzani, S. Milani, C. Grappone, F.L. Weber, P. Gentilini, H.E. Abboud.
Expression of platelet derived growth factor and its receptors in a model of acute liver injury.
Hepatology, 19 (1994), pp. 701-707
[11.]
M. Pinzani, S. Milani, H. Herbst, R. De Franco, C. Grappone, A. Gentilini, et al.
Expression of platelet derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis.
Am J Pathol, 148 (1996), pp. 785-800
[12.]
C.J. Marshal.
Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.
Cell, 80 (1995), pp. 179-185
[13.]
F. Marra, A. Gentilini, M. Pinzani, G.G. Choudhury, M. Parola, H. Herbst, et al.
Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's actions on hepatic stellate cells.
Gastroenterology, 112 (1997), pp. 1297-1306
[14.]
G. Robino, M. Parola, F. Marra, A. Caligiuri, R.M. De Franco, E. Zamara, et al.
Interaction between 4-hydroxy-2,3-alkenals and the platelet-derived growth factor-beta receptor. Reduced tyrosine phosphorylatin and downstream signaling in hepatic stellate cells.
J Biol Chem, 275 (2000), pp. 40561-40567
[15.]
M. Pinzani, F. Marra, A. Caligiuri, R. De Franco, A. Gentilini, P. Failli, et al.
Inhibition by pentoxifylline of extracellular signal-regulated kinase activation by platelet-derived growth factor in hepatic stellate cells.
Br J Pharmacol, 119 (1996), pp. 1117-1124
[16.]
A. Mallat, C. Gallois, J. Tao, A. Habib, J. Machouf, P. Mavier, et al.
Platelet-derived growth factor-BB and thormbin generate positive and negative signals for human hepatic stellate cell proliferation. Role of a prostaglandin/cyclic AMP pathway and cross-talk with endothelin receptors.
J Biol Chem, 273 (1998), pp. 27300-27305
[17.]
S.R. Datta, A. Brunet.
Cellular survival: a play in three Akts.
Genes Dev, 13 (1999), pp. 2905-2927
[18.]
R. Mancini, A. Benedetti, A.M. Jezequel.
An interleukin-1 receptor antagonist decreases fibrosis induced by dimethylnitrosamine in rat liver.
Virchows Arch, 424 (1994), pp. 25-31
[19.]
V. Ankoma-Sey, Y. Wang, Z. Dai.
Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells.
Hepatology, 31 (2000), pp. 141-148
[20.]
A. Castilla, J. Prieto, N. Fausto.
Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy.
N Engl J Med, 324 (1991), pp. 933-940
[21.]
S.L. Friedman.
Cytokines and fibrogenesis.
Semin Liver Dis, 19 (1999), pp. 129-140
[22.]
D.M. Bissel, S.S. Wang, W.R. Jarnagin, F.J. Roll.
Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation.
J Clin Invest, 96 (1995), pp. 447-455
[23.]
D.S. Yoo, D.C. Rockey.
Endothelin receptor subtypes in liver injury: upregulation and differential signaling in myofibroblast contractility.
Hepatology, 32 (2000), pp. 328
[24.]
J. Massague.
How cells read TGF-beta signals.
Nat Rev Mol Cell Biol, 1 (2000), pp. 169-178
[25.]
M. Pinzani, S. Milani, R. De Franco, C. Grappone, A. Caligiuri, A. Gentilini, et al.
Endothelin-1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells.
Gastroenterology, 110 (1996), pp. 534-548
[26.]
J. Alam, N.M. Bass, P. Bacchetti, L. Gee, D.C. Rockey.
Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites.
Am J Gastroenterol, 95 (2000), pp. 199-203
[27.]
A. Mallat, F. Fouassier, A.M. Preaux, C.S. Gal, D. Raufaste, J. Rosenbaun, et al.
Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic Ito cells: an endothelin B receptor-mediated pathway.
J Clin Invest, 96 (1995), pp. 42-49
[28.]
R. Bataller, P. Ginés, J.M. Nicolás, M.N. Gorgib, E. García-Ramallo, V. Gasull, et al.
Angiotensin II induces contraction and proliferation of human hepatic stellate cells.
Gastroenterology, 118 (2000), pp. 1149-1156
[29.]
M. Pinzani, P. Failli, C. Ruocco, A. Casini, S. Milani, E. Baldi, et al.
Fat-storing cells as liver-specific pericytes: spatial dynamics of agonist-stimulated intracellular calcium transients.
J Clin Invest, 90 (1992), pp. 642-646
[30.]
F. Marra.
Hepatic stellate cells and the regulation of liver inflammation.
J Hepatol, 31 (1999), pp. 1120-1130
[31.]
E.C. Ledgerwood, J.S. Pober, J.R. Bradly.
Recent advances in the molecular basis of TNF signal transduction.
Lab Invest, 79 (1999), pp. 1041-1050
[32.]
T. Knittel, L. Muller, B. Saile, G. Ramadori.
Effect of tumour necrosis factor-alpha on proliferation, activation and protein synthesis of rat hepatic stellate cells.
J Hepatol, 27 (1997), pp. 1067-1080
[33.]
B. Saille, T. Knittel, N. Matthes, P. Schott, G. Ramadori.
CD95/CD95L-mediated apoptosis of the hepatic stellate cells. A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair.
Am J Pathol, 151 (1997), pp. 1265-1272
[34.]
N. Trim, S. Morgan, M. Evans, R. Issa, D. Fine, S. Afford, et al.
Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation.
Am J Pathol, 156 (2000), pp. 1235-1243
[36.]
M. Buck, D.J. Kim, K. Houglum, T. Hassanein, M. Chojkier.
c-myb modulates transcription of the alpha-smooth muscle actin gene in activated hepatic stellate cells.
Am J Physiol Gastrointest Liver Physiol, 278 (2000), pp. G321-G328
[37.]
P. Greenwel, J.A. Domínguez-Rosales, G. Mavi, A.M. Rivas-Estilla, M. Rojkind.
Hydrogen peroxide: a link between acetaldehyde-elicited alpha1(I) collagen gene upregulation and oxidative stress in mouse hepatic stellate cells.
Hepatology, 31 (2000), pp. 109-116
[38.]
M.J. Iraburu, J.A. Domínguez-Rosales, L. Fontana, A. Auster, E.R. García-Subijano, A. Covarrubias-Pinedo, et al.
Tumor necrosis factor alpha down-regulates expression of the alpha1(I) collagen gene in rat hepatic stellate cells through a p20C/EBPbeta-and C/EBPdelta-dependent mechanism.
Hepatology, 31 (2000), pp. 1086-1093
[39.]
A. Lang, R. Schonhoven, S. Tuvia, D.A. Brenner, R.A. Rippe.
Nuclear factor kappa B in proliferatrion, activation and apoptosis in rat hepatic stellate cells.
J Hepatol, 33 (2000), pp. 58
[40.]
D. Schuppan.
Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins.
Semin Liv Dis, 10 (1990), pp. 1-10
[41.]
B.H. Davis.
Transforming growth factor beta responsiveness is modulated by the extracellular collagen matrix during hepatic ito cell culture.
J Cell Physiol, 136 (1988), pp. 547-553
[42.]
M. Chiquet, M. Matthisson, M. Koch, M. Tannheimer, R. Chiquet-Ehrismannn.
Regulation of extracellular matrix synthesis by mechanical stress.
Biochem Cell Biol, 74 (1996), pp. 737-744
[43.]
D.C. Rockey, R.A. Weisiger.
Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance.
Hepatology, 24 (1996), pp. 240
[44.]
N. Kawada, T.A. Tran-Thi, H. Klein, K. Decker.
The contraction of hepatic stellate (Ito) cells stimulated with vasoactive abustances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus.
Eur J Biochem, 213 (1993), pp. 823
[45.]
M. Asbert, A. Gines, P. Gines.
Circulating levels of endothelin in cirrhosis.
Gastroenterology, 104 (1993), pp. 1485-1491
[46.]
S. Moncada, A. Higgs.
The L-arginine-nitric oxide pathway.
N Engl J Med, 329 (1993), pp. 2002-2012
[47.]
T.K. Gupta, M. Toruner, M.K. Chung, R.J. Groszmann.
Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats.
Hepatology, 28 (1998), pp. 926-931
[48.]
Q. Yu, R. Shao, H.S. Qian, S.E. George, D.C. Rockey.
Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension.
J Clin Invest, 105 (2000), pp. 741-748
[49.]
M. Prieto, M. Berenguer, A. Rimola, C. Losnaz, C. Barrios, G. Clemente, et al.
Liver Transplantation in hepatitis C: a Spanish multicenter experience.
Eur J Gastroenterol Hepatol, 10 (1998), pp. 771-776
[50.]
J.G. O'Grady, H.M. Smith, S.E. Davies, H.M. Daniels, P.T. Donaldson, K.C. Tan, et al.
Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications.
J Hepatol, 14 (1992), pp. 104-111
[51.]
O. Chazouilleres, D. Mamish, M. Kim, K. Casey, L. Ferrell, J.P. Roberts, et al.
«Occult» hepatitis B virus as source of infection in liver transplant recipients.
Lancet, 343 (1994), pp. 142
[52.]
T. Wright, E. Donegan, H. Hsu, L. Ferrell, J.R. Lake, M. Kim, et al.
Recurrent and acquired hepatitis C viral infection in liver transplant recipients.
Gastroenterology, 103 (1992), pp. 317-322
[53.]
M. Prieto, M. Berenguer, M. Rayon, J. Cordoba, L. Arguello, D. Carrasco, et al.
High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
Hepatology, 29 (1999), pp. 250-256
[54.]
M. Berenguer, L. Ferrell, J. Watson, M. Prieto, R. Kim, M. Rayon, et al.
HCV-related fibrosis progression following liver transplantation: increase in recent years.
J Hepatol, 32 (2000), pp. 673-684
[55.]
C. Feray, L. Caccamo, G.J.M. Alexander, G.S. Alexander, B. Ducot, V. Gugenheim, et al.
European Collaborative Study on factors influencing the outcome after liver transplantation for hepatitis C.
Gastroenterology, 117 (1999), pp. 619-625
[56.]
M. Charlton, E. Seaberg, R. Wiesner, J. Ferharst, R. Zetterman, J. Lake, et al.
Predictors of patient and graft survival following liver transplantation forhepatitis C.
Hepatology, 28 (1998), pp. 823-830
[57.]
M. Berenguer, M. Prieto, J.M. Rayon, J. Mora, M. Pastor, V. Ortiz, et al.
Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation.
Hepatology, 32 (2000), pp. 852-858
[58.]
M. Berenguer, M. Prieto, F. San Juan.
Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.
Hepatology, 36 (2002), pp. 202-210
[59.]
L.M. Forman, J.D. Lewis, J.A. Berlin, H.I. Feldman, M.R. Lucey.
The association between hepatitis C infection and survival after orthotopic liver transplantation.
Gastroenterology, 122 (2002), pp. 889-896
[60.]
M. Berenguer, M. Rayon, M. Prieto, V. Aguilera, D. Nicolas, V. Ortiz, et al.
Are post-transplantation protocol liver biopsies useful in the long-term?.
Liver transp, 7 (2001), pp. 790-796
[61.]
M. Guido, M. Rugge, G. Leandro, I. Fiel, S. Thung.
Hepatic stellate cel immunodetection and cirrhotic evolution of viral hepatitis in liver allografts.
Hepatology, 26 (1997), pp. 310-314
[62.]
K.W. Burak, W. Kremers, K. Batts, R.H. Wiesner, C.B. Rosen, R.R. Razonable, et al.
Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.
Liver Transpl, 8 (2002), pp. 362-369
[63.]
D. Samuel, R. Mueller, G. Alexander, L. Fassati, B. Ducot, S.P. Benhamou, et al.
Liver transplantation in European patients with the hepatitis B surface antigen.
N Engl J Med, 329 (1993), pp. 1842-1847
[64.]
Y.O. Kweon, Z.D. Goodman, J.L. Dienstag, E.R. Schiff, N.A. Brown, E. Burchardt, et al.
Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B.
J Hepatol, 35 (2001), pp. 749-755
[65.]
S.E. Davies, B.C. Portmann, J.G. O'Grady, P.M. Aldis, K. Chaggar, G.J. Alexander, et al.
Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis.
Hepatology, 13 (1991), pp. 150-157
[66.]
T.W. Faust.
Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation.
Liver Transpl, 7 (2001), pp. 99-108
[67.]
R. Bataller, D.A. Brenner.
Hepatic stellate cells as a target for the treatment of liver fibrosis.
Semin Liver Dis, 21 (2001), pp. 437-451
[68.]
J.F. Dufour, DeLellis, R, M.M. Kaplan.
Reversibility of hepatic fibrosis in autoinmune hepatitis.
Ann Intern Med, 127 (1997), pp. 981-985
[69.]
J.A. Solis, J.D. Morillas, M.T. Munoz.
Fibrogenesis hepatica.
Enfermedades digestivas. Tomo 3: Higado y vias biliares, pp. p1775-p1785
[70.]
D.W. Beno, R. Espinal, B.M. Edelstein, B.H. Davis.
Administration of prostaglandin E analogue reduces rat hepatic and Ito cell collagen gene expression and collagen accumulation after bile duct ligation injury.
Hepatology, 17 (1993), pp. 707-714
[71.]
A. Rambaldi, C. Gluud.
Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis.
Liver, 21 (2001), pp. 129-136
[72.]
H. Cortez-Pinto, P. Alexandrino, M.E. Camilo, A. Gouveia-Oliveira, P.M. Santos, M.M. Alves, et al.
Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial.
Eur J Gastroenterol Hepatol, 14 (2002), pp. 377-381
[73.]
M.G. Chiaramonte, A.W. Cheever, J.D. Malley, D.D. Donaldson, T.A. Wynn.
Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis.
Hepatology, 34 (2001), pp. 273-282
[74.]
S. Dharancy, V. Canva, L. Gambiez, J.C. Paris, P. Desreumaux.
Hepatic deficiency of interleukin 10 in chronic hepatitis C.
Gastroenterology, 119 (2000), pp. 1411
[75.]
D.R. Nelson, G.Y. Lauwers, J.Y. Lau, G.L. Davis.
Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders.
Gastroenterology, 118 (2000), pp. 655-660
[76.]
C. Gluud, E. Christensen.
Ursodeoxycholic acid for primary biliary cirrhosis.
Cochrane Database Syst Rev, (2002), pp. CD000551
[77.]
K. Houglum, A. Venkataramani, K. Lyche, M. Chojkier.
A pilot study of the effects of d-α-tocopherol on hepatic stellate cell activation in chronic hepatitis C.
Gastroenterology, 113 (1997), pp. 1069-1073
[78.]
A. Pares, R. Planas, M. Torres, J. Caballeria, J.M. Viver, D. Acero, et al.
Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial.
J Hepatol, 26 (1998), pp. 615-621
[79.]
H. Tsushima, S. Kawata, S. Tamura, N. Ito, Y. Shirai, S. Kiso, et al.
Reduced plasma transforming growth factor-β levels in patients with chronic hepatitis C after interferon-α therapy: association with regression of hepatic fibrosis.
J Hepatol, 30 (1999), pp. 1-7
[80.]
J. George, D. Roulot, V.E. Koteliansky, D.M. Bisell.
In vivo inhibition of rat stellate cell activation by soluble TGF beta type II receptor: a potential new therapy for hepatic fibrosis.
Proc Natl Acad Sci USA, 96 (1999), pp. 12719-12724
[81.]
Y. Yata, P. Gotwals, V. Koteliansky, D.C. Rockey.
Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-β soluble receptor: implications for antifibrotic therapy.
Hepatology, 35 (2002), pp. 1022-1030
[82.]
D.M. Bissell, D. Roulot, J. George.
Transforming growth factor β and the liver.
Hepatology, 34 (2001), pp. 859-867
[83.]
G.S. Baroni, L. D'Ambrosio, P. Curto, A. Casini, R. Manzini, A.M. Jezequel, et al.
Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis.
Hepatology, 23 (1996), pp. 1189-1199
[84.]
I. Sakaida, K. Uchida, Y. Matsumura, K. Okita.
Interferon gamma treatment prevents procollagen gene expression without affecting transforming growth factor-beta 1 expression in pig serum-induced rat liver fibrosis in vivo.
J Hepatol, 28 (1998), pp. 471-479
[85.]
H.L. Weng, W.M. Cai, R.H. Liu.
Animal experiment and clinical study of effect of gamma-interferon on hepatic fibrosis.
World J Gastroenterol, 7 (2001), pp. 42-48
[86.]
T. Poynard, J. McHutchison, G.L. Davis, R. Esteban-Mur, Z. Goodman, P. Bedossa, et al.
Impact of interferon alfa-2b and ribavirina on progression of liver fibrosis in patients with chronic hepatitis C.
Hepatology, 32 (2000), pp. 1131-1137
[87.]
R. Sobesky, P. Mathurin, F. Charlotte, J. Moussali, M. Olivi, M. Vidaud, et al.
Modelling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view.
Gastroenterology, 116 (1999), pp. 378-386
[88.]
A. Gallorini, M. Plebani, P. Pontisso, L. Chemello, M. Masiero, G. Mantovani, et al.
Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2a interferon.
Liver, 14 (1994), pp. 257-264
[89.]
K. Ishibashi, T. Kashiwagi, A. Ito, Y. Tanaka, M. Nagasawa, T. Toyama, et al.
Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C.
Hepatology, 24 (1996), pp. 27-31
[90.]
T. Suou, K. Hosho, Y. Kishimoto, Y. Horie, H. Kawasakia.
Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa.
Hepatology, 22 (1995), pp. 426-461
[91.]
L. Mazzoran, G. Tamaro, M.A. Mangiarotti, P. Marchi, S. Baracetti, U. Gerini, et al.
Effects of interferon therapy on fibrosis serum markers in HCV-positive chronic liver disease.
Eur J Gastroenterol Hepatol, 10 (1998), pp. 125-131
[92.]
A. Mitsuda, T. Suou, Y. Ikuta, H. Kawasaki.
Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C.
J Hepatol, 32 (2000), pp. 666-672
[93.]
F. Serejo, A. Costa, A. Gouveia, F. Ramalho, A. Batista, M. Carneiro de Moura.
α-interferon improves liver fibrosis in chronic hepatitis C. Clinical significance of the serum N-terminal propeptide of procollagen type III.
Dig Dis Sci, 46 (2001), pp. 1684-1689
[94.]
M. Bueno, A. Daneri, J. Armendariz-Borunda.
Colestasis-induced fibrosis is reduced by interferon α2a and is associated with elevated liver metalloprotease activity.
J Hepatol, 33 (2000), pp. 915-925
[95.]
B. Lavezzo, A. Franchello, A. Smedile, et al.
Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus twelve month course of interferon alfa 2b with ribavirin.
J Hepatol, 37 (2002), pp. 247-252
[96.]
A. Desmouliere, X. Guoxiong, A.M. Costa, I.M. Yousef, G. Gabbiani, B. Tuchweber.
Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells.
J Hepatol, 30 (1999), pp. 621-631
[97.]
C. Raetsch, J.D. Jia, G. Boigk, M. Bauer, E.G. Hahn, E.O. Riecken, et al.
Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis.
Gut, 50 (2002), pp. 241-247
[98.]
A. Mallat, A.M. Preaux, S. Blazejewski, D. Dhumeaux, J. Rosenbaum, P. Mavier.
Effect of simvastatin, an inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells.
Hepatology, 20 (1994), pp. 1589-1594
[99.]
J. Zhu, J. Wu, E. Frizell, S.L. Liu, R. Bashey, R. Rubin, et al.
Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis.
Gastroenterology, 117 (1999), pp. 1198-1204
[100.]
J. Davaille, C. Gallois, A. Habib, L. Li, A. Mallat, J. Tao, et al.
Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts.
J Biol Chem, 275 (2000), pp. 34628-34633
[101.]
I. Shimizu, Y. Mizobuchi, M. Yasuda, M. Shiba, Y.R. Ma, T. Horie, et al.
Inhibitory effect of oestradiol on activation of rat hepatic stellate cells in vivo and in vitro.
Gut, 44 (1999), pp. 127-136
[102.]
G. Paizis, R.E. Gilbert, M.E. Cooper, P. Murthi, J.M. Schembri, L.L. Wu, et al.
Effect of angiotensin II type I receptor blockade on experimental hepatic fibrosis.
J Hepatol, 35 (2001), pp. 376-385
[103.]
H. Yoshiji, S. Kuriyama, J. Yoshii, Y. Ikenaka, R. Noguchi, T. Nakatani, et al.
Angiotensin-II type I receptor interaction is a major regulator for liver fibrosis development in rats.
Hepatology, 34 (2001), pp. 745-750
[104.]
J. Vlachogiannakos, A.K. Tang, D. Patch, A.K. Burroughs.
Angiotensine converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.
Gut, 49 (2001), pp. 303-308
[105.]
J.J. Cho, B. Hocher, H. Herbst, J.D. Jia, M. Ruehl, E.G. Hahn, et al.
An oral endothelin A-receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis.
Gastroenterology, 118 (2000), pp. 1169-1178
[106.]
L. Dubuisson, A. Desmouliere, B. Decourt, L. Evade, C. Bedin, L. Boussarie, et al.
Inhibition of rat liver fibrogenesis through noradrenergic antagonism.
Hepatology, 35 (2002), pp. 325-331
[107.]
P. Failli, R.M. DeFranco, A. Caligiuri, A. Gentilini, R.G. Romanelli, F. Marra, et al.
Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells.
Gastroenterology, 179 (2000), pp. 479-492
[108.]
K. Okita, I. Sakaida, K. Hino.
Current strategies for chemoprevention of hepatocelular carcinoma.
Oncology, 62 (2002), pp. 24-28
[109.]
X.L. Zhang, L. Liu, H.Q. Jiang.
Salvia miltiorrhiza monomer IH 764-3 induces hepatic stellate cell apoptosis via caspase-3 activation.
World J Gastroenterol, 8 (2002), pp. 515-519
[110.]
P. Liu, Y. Hu, C. Liu, C. Liu, D. Zhu.
Effects of salviainolic acid A (SA-A) on liver injury: SA-A action on hepatic peroxidation.
Liver, 21 (2001), pp. 384-390
[111.]
S. Wasser, J.M. Ho, H.K. Ang, C.E. Tan.
Salvia miltiorrhiza reduces experimentally-induced hepatic fibrosis in rats.
J Hepatol, 29 (1998), pp. 760-771
[112.]
H. Kumada.
Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma.
Oncology, 62 (2002), pp. 94-100
[113.]
M. Watanabe, Y. Uchida, S. Sato, M. Moritani, S. Hamamoto, T. Mishiro, et al.
Report of a case showing a recovery from liver cirrhosis to chronic hepatitis, type C after glycyrrhizin injection for 2 years and a sustained response by the following interferon therapy.
Am J Gastroenterol, 96 (2001), pp. 1947-1949
[114.]
I. Sakaida, K. Uchida, K. Hironaka, K. Okita.
Prolyl 4-hydroxylase inhibitor (HOE 077) prevents TIMP-1 gene expression in rat liver fibrosis.
J Gastroenterol, 34 (1999), pp. 376-377
[115.]
M. Aoyagi, I. Sakaida, C. Suzuki, M. Segawa, Y. Fukumoto, K. Okita.
Prolyl 4-hydroxylase inhibitor is more effective for the inhibition of proliferation than for inhibition of collagen synthesis of rat hepatic stellate cells.
Hepatol Res, 23 (2002), pp. 1-6
[116.]
I. Sakaida, Y. Matsumura, M. Kubota, K. Kayano, K. Takenaka, K. Okita.
The prolyl 4-hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline-deficient Lamino acid-defined diet.
Hepatology, 23 (1996), pp. 755-763
[117.]
M. Pines, V. Knopov, O. Genina, I. Lavelin, A. Nagler.
Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis.
J Hepatol, 27 (1997), pp. 391-398
[118.]
R. Bruck, O. Genina, H. Aeed, R. Alexiev, A. Nagler, Y. Avni, et al.
Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats.
Hepatology, 33 (2001), pp. 379-386
[119.]
G. Spira, N. Mawasi, M. Paizi, N. Anbinder, O. Genina, R. Alexiev, et al.
Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats.
J Hepatol, 37 (2002), pp. 331-339
[120.]
A. Hagler, M. Pines.
Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis.
Transplantation, 68 (1999), pp. 1806-1809
[121.]
R. Hernandez-Munoz, M. Diaz-Munoz, J.A. Suarez-Cuenca, C. Trejo-Solis, V. Lopez, L. Sanchez-Sevilla, et al.
Adenosine reverses a preestablished CCl4 -induced micronodular cirrhosis through enhancing collagenolytic activity and stimulating hepatocyte cell proliferation in rats.
Hepatology, 34 (2001), pp. 677-687
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
